Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Patent: 10,260,097

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,260,097
Title:Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.
Inventor(s): Harkin; Denis Paul (Dromore, GB), Patterson; Fionnuala (Greenisland, GB), Trinder; Claire (Stratford-upon-Avon, GB), O\'Brien; Eamonn J. (Hillsborough, GB), Michie; Caroline (Nr Kirkcaldy, GB), Gourley; Charlie (Dumfermline, GB), Hill; Laura A. (Lisburn, GB), Keating; Katherine E. (Magherafelt, GB), O\'Donnell; Jude (Galbally, GB), Bylesjo; Max (Glasgow, GB), Deharo; Steve (Hillsborough, GB), Proutski; Vitali (Oxford, GB), Kennedy; Richard (Belfast, GB), Davison; Timothy (Hillsborough, GB), Winter; Andreas (Gersthofen, DE), McCavigan; Andrena (Derryadd Lurgan, IE)
Assignee: Almac Diagnostics Limited (Craigavon, GB)
Application Number:14/123,406
Patent Claims:see list of patent claims

Details for Patent 10,260,097

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Eli Lilly And Co CYRAMZA ramucirumab INJECTABLE;INJECTION 125477 002 2014-04-21   Start Trial Almac Diagnostics Limited (Craigavon, GB) 2031-06-02 RX Orphan search
Eli Lilly And Co CYRAMZA ramucirumab INJECTABLE;INJECTION 125477 001 2014-04-21   Start Trial Almac Diagnostics Limited (Craigavon, GB) 2031-06-02 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Almac Diagnostics Limited (Craigavon, GB) 2031-06-02 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.